Stock info Nektar Therapeutics | Filter  Basic-Info

Nektar Therapeutics

The past year was a profitable year Nektar Therapeutics investors

Over the last 12 months, that were loss-making period for the investors in Nektar Therapeutics, the stock lost around 19 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 151 percent. Nektar Therapeutics's revenues between 2011 and 2015 were very volatile and moved between 81,19 million dollars and 230,78 million dollars. Nektar Therapeutics's net incomes between 2011 and 2015 were very volatile and moved between -133,98 million dollars and -81,18 million dollars.

The company mostly operates in the pharmaceutical sector. The global pharmaceutical companies gained over the past 10 years on average 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The American company didn't pay out any dividends (in the past 5 years).

Nektar Therapeutics financed with a quite low debt position

As per the end of 2015 the American company's balance sheet equaled 502,06 million dollars. Last year the total debt of the company was 495,63 million dollars. This equals around 98,72 percent of the total balance sheet. The American company's price/earnings-ratio was -29. So the market valued the stock at -29 times the 2015' earnings per share. We could say that based on her price/earnings-ratio and dividend yield the American stock can be seen as a growth stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the pharmaceutical company equaled around 2,19 billion dollars. At the end of 2015 the American company had around 132,46 million stocks listed.

All Nektar Therapeutics's financial reports are available here. More information about Nektar Therapeutics can be found it's website. .